A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design

BACKGROUND: Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease requiring kidney transplantation and can recur in the allograft in 30-80% of recipients resulting in reduced graft survival. Plasmapheresis has shown efficacy in treating some cases of recurrent FSGS...

Descripción completa

Detalles Bibliográficos
Autores principales: Rheault, Michelle N., Amaral, Sandra, Bock, Margret, Chambers, Eileen Tsai, Chavers, Blanche, Ters, Mireile El, Garro, Rouba, Gbadegesin, Rasheed, Govil, Amit, Harshman, Lyndsay, Amer, Hatem, Hooper, David K., Israni, Ajay K., Riad, Samy, Sageshima, Junichiro, Shapiro, Ron, Seifert, Michael, Smith, Jodi, Sung, Randall, Thomas, Christie P., Wang, Qi, Verghese, Priya S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Nephrology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479749/
https://www.ncbi.nlm.nih.gov/pubmed/37675355
http://dx.doi.org/10.3389/fneph.2023.1181076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479749/
https://www.ncbi.nlm.nih.gov/pubmed/37675355
http://dx.doi.org/10.3389/fneph.2023.1181076

Ejemplares similares